

# The effect of Pheroid<sup>®</sup> technology on the bioavailability of artemisone in primates

**L Grobler**

**13065513**

**BSc, M.Sc. (Biochemistry)**

Thesis submitted for the degree Philosophiae Doctor in  
Pharmaceutics at the Potchefstroom Campus of the North-West  
University

Promoter: Prof. A.F. Grobler  
Co-promoter: Prof. R.K. Haynes

May 2014

## ACKNOWLEDGEMENTS

Foremost, I would like to express my sincere gratitude to God for giving me this opportunity.

This thesis could not have been written without the encouragement and generous assistance of countless individuals.

Rick Grobler, my husband, thank you for all the love and patience. Thank you for being there through times of tears and smiles and all of the sacrifices that you had to make. Your spiritual support and encouragement throughout this journey really meant the world to me.

J.P and Elmarie Meeding, my parents, thank you for your financial and emotional support. I could not have asked for better parents and am proud to be your daughter. Thank you for giving me this opportunity and never giving up on me.

Hans and Denise Grobler, my parents-in-law, thank you for your love, understanding and encouragement. Thank you for accepting me as your own daughter and supporting me in a way that you do with your own children.

Prof. Anne Grobler, my promoter, thank you for the opportunity to do my PhD in Pharmaceutics. Thank you for all your advice and for your inputs throughout the process of my research. Thank you for the funding and enabling me to visit other laboratories and meet amazing people.

Prof Richard Haynes, my co-promoter, thank you for your enthusiasm for my work. Thank you for always having an open door. I appreciate the way you shared your vast knowledge on malaria and your assistance in the writing of this thesis.

Mike, Marina and Kerryn, my colleagues from the army malaria institute in Australia, thank you for making my visit there a memorable and enjoyable one. I really learned so much from you and was truly blessed by the way I was received in your laboratories. Mike and Maria, thank you for opening your home for me, for all the beautiful places you showed me and the delicious food.

Liezl Gibhard, my PhD buddy, as we walked this road together, I thank God that I could share all those times in the laboratory with you. Whether it was early mornings, late nights or labelling tubes until the break of dawn, we got through it together. I will always remember

and treasure the verse that God gave us for our PhD's. Rom 5:3-5 "And not only *this*, but we glory in afflictions also, knowing that afflictions work out patience, and patience *works out* experience, and experience *works out* hope."

I would also like to thank my friends and colleagues for your encouragement, prayers and support.

Lizette Grobler

This thesis is submitted in fulfilment of the requirements of a Doctor of Philosophy in Pharmaceutics. This study forms part of the project T90020: “An investigation into drug resistance reversal of antimalarials using Pheroid™ technology” and was financially supported by the South African Technology Innovation Agency (TIA), the Swiss South African Joint Research Project Initiative and the North-West University. This thesis is submitted in a manuscript format in accordance with the General Academic Rules (A.7.5.7.4) of the North-West University. Each chapter is written in accordance with specific guidelines as stipulated by the journals intended for publication. Manuscript 1 has been submitted to *Expert Opinion on Drug Metabolism and Toxicology*, manuscript 2 will be submitted to *Antimicrobial Agents and Chemotherapy* and manuscript 3 will be submitted to *The International Journal for Parasitology – Drugs and Drug Resistance*

The contribution of each author is as follows:

L. Grobler (Candidate)

- Planning and design of the studies.
- Experimental work.
- Interpretation of results.
- Writing of the thesis and manuscripts.
- Corresponding author of manuscripts.

Prof. A.F. Grobler (Promotor)

- Supervision of the planning and design of the studies.
- Assistance in the interpretation of results.
- Supervision and critical review of the writing of the thesis and manuscripts.
- Corresponding author of manuscripts.

Prof. R.K. Haynes (Co-promotor)

- Supervision of the planning and design of the studies.
- Assistance in the interpretation of results.
- Supervision and critical review of the writing of the thesis and manuscripts.
- Supplied artemisone and metabolite M1.

Prof. P.A. Steenkamp

- Critical review of the writing of the manuscripts 1 and 3.
- Performed the UPLC-QTOF-MS analysis.
- Assistance in the interpretation of metabolism and p-gp results.

Prof. C. Masimirembwa

- Critical review of the writing of the manuscript 1.
- Supervision of the planning and design of the metabolism study.
- Assistance in the interpretation of the metabolism results.

Mrs. R. Thelingwani

- Experimental work and assistance in the interpretation of the metabolism results.

Prof. H.S. Steyn

- Performed the statistical analysis.
- Critical review of the writing of the manuscripts.

Dr M. Chavchich

- Critical review of the writing of manuscript 2.
- Supplied *P. falciparum* isolates.
- Supervision of the planning and design of the *in vitro* efficacy and dormancy study.
- Experimental work and assistance in the interpretation of the *in vitro* efficacy and dormancy study.

Prof. M. D. Edstein


- Critical review of the writing of the manuscript 2.
- Supplied *P. falciparum* isolates.
- Supervision of the planning and design of the *in vitro* efficacy and dormancy study.
- Assistance in the interpretation of the *in vitro* efficacy and dormancy study.

Prof. H. J. Viljoen


- Set up of the mathematical model of the caco-2 study and assistance in the interpretation thereof.

## Declarations

I hereby declare that I have approved the manuscripts/thesis and that my role in the study as indicated above is representative of my actual contribution. I give permission as author or co-author for submission of the manuscripts/thesis for degree purposes.



L. Grobler




Prof. A.F. Grobler




Prof. R.K. Haynes




Prof. P.A. Steenkamp



Prof. C. Masimirembwa



Mrs. R. Thelingwani



Prof. F. Steyn



Dr M. Chavchich



Prof. M. D. Edstein



Prof. H. J. Viljoen

## ABSTRACT

Malaria is one of the world's most devastating diseases. Several classes of drugs are used to treat malaria. Artemisinin combination therapy is the first line treatment of uncomplicated malaria. The artemisinin derivative, artemisone in conjunction with the Pheroid® drug delivery system, is the focus of this thesis.

The impact of the Pheroid® on the bioavailability of artemisone was evaluated in vervet monkeys. The resulting artemisone plasma levels were much lower ( $C_{max}$  of 47 and 114 ng/mL for reference and Pheroid® test formulations respectively) than expected for the dosages administered (60 mg/kg). The Pheroid® improved the pharmacokinetic profile of artemisone in a clinically significant manner. The metabolism of artemisone was assessed *in vitro* by using human and monkey liver and intestinal microsomes, and recombinant CYP3A4 enzymes. The Pheroid® inhibits the microsomal metabolism of artemisone. In addition, there is a species difference in artemisone metabolism between man and monkey since the *in vitro* intrinsic clearance of the reference formulation with monkey liver microsomes is ~8 fold higher in the monkey liver microsomes compared to the human liver microsomes and the estimated *in vivo* hepatic clearance for the monkey is almost twofold higher than in humans.

Artemisone has potent antimalarial activity. Its *in vitro* efficacy was approximately twofold higher than that of either artesunate or dihydroartemisinin when evaluated against *P. falciparum* W2, D6, 7G8, TM90-C2B, TM91-C235 and TM93-C1088 parasite strains. The Pheroid® drug delivery system did not improve or inhibit the *in vitro* efficacy of artemisone or DHA. Artemisone (reference and Pheroid® test formulations) and metabolite M1 abruptly arrested the growth of *P. falciparum* W2 parasites and induced the formation of dormant ring stages in a manner similar to that of DHA.

Interaction of artemisone with the p-glycoprotein (p-gp) efflux transporter was investigated. Artemisone stimulates ATPase activity in a concentration-dependent manner, whereas the Pheroid® inhibited this p-gp ATPase activity. P-gp ATPase activity stimulation was fourfold greater in human than cynomolgus monkey MDR1 expressed insect cell membranes. Artemisone alone and artemisone entrapped in Pheroid® vesicles showed moderate apical to basolateral and high basolateral to apical permeability ( $P_{app}$ ) across Caco-2 cells. The  $P_{app}$  efflux ratio of artemisone and artemisone entrapped in Pheroid® vesicles were both >5, and decreased to ~1 when the p-gp inhibitor, verapamil, was added. Therefore, artemisone is a substrate for mammalian p-gp. The cytotoxic properties of Pheroid® on Caco-2 cells were assessed and the pro-Pheroid® seems to be non-toxic at concentrations of ≤1.25%.

Vervet monkey plasma caused antibody-mediated growth inhibition of *P. falciparum*. Heat inactivated or protein A treatment proved useful in the elimination of the growth-inhibitory activity of the drug-free plasma. Plasma samples containing artemisone could not be analysed by the *ex-vivo* bioassay method. The dual labelling ROS assay did not prove to be useful in the evaluation of ROS production by artemisone and the Pheroid® delivery system.

In conclusion, entrapment of artemisone in the Pheroid® delivery system improves the pharmacokinetic properties of artemisone, but does not improve or inhibit its antimalarial efficacy *in vitro*. The Pheroid® inhibited both the microsomal metabolism of artemisone and P-gp ATPase activity and was shown to be non-toxic at clinically usable concentrations.

**Keywords:** artemisone, bioavailability, clearance, drug delivery, efficacy, malaria, metabolism, monkey, Pheroid®.

## UITTREKSEL

Malaria is een van die wêreld se mees verwoestende siektes. Verskeie geneesmiddelklasse word gebruik om malaria te behandel. Artemisinin gebaseerde kombinasie terapie is die eerste linie van behandeling van ongekompliseerde malaria. Die artemisinin derivaat, artemisoon, in kombinasie met die Pheroid® geneesmiddel afleweringssisteem, is die fokus van hierdie proefskrif.

Die impak van die Pheroid® op die biobeskikbaarheid van artemisoon is geëvalueer in blouape. Die artemisoon plasma vlakke was laer ( $C_{max}$  van 47 en 114 ng/mL vir verwysing en Pheroid® toets formulering onderskeidelik) as wat verwag is vir die dosis wat toegedien is (60 mg/kg). Inkorporering van artemisoon in die Pheroid® afleweringssisteem het die farmakokinetiese profiel van artemisoon op 'n klinies beduidende wyse verbeter. Die metabolisme van artemisoon is beoordeel *in vitro* deur die gebruik van 5 toetsisteme: menslike lewer, aaplewer, menslike en aap intestinale mikrosome, en die rekombinante ensiem CYP3A4. Die Pheroid® inhibeer die mikrosomale metabolisme van artemisoon. Daarbenewens is daar 'n spesie verskil in artemisoon metabolisme tussen mens en aap aangesien die *in vitro* intrinsieke opruiming van die verwysing formulering gemeet in aap lewer mikrosome ~8 keer hoër is in die aap lewer mikrosome in vergelyking met die menslike lewer mikrosome. Die beraamde *in vivo* hepatiese opruiming vir die aap is byna twee keer hoër as in die mens.

Artemisoon toon goeie anti-malaria effektiwiteit *in vitro*. Die effektiwiteit was ongeveer twee keer hoër as dié van óf artesunaat óf dihydroartemisinin teen *P. falciparum* W2 , D6 , 7G8 , TM90 - C2B , TM91 - C235 en TM93 - C1088 parasiet isolate in *in vitro* effektiwiteits toetse. Die Pheroid® het nie die *in vitro* effektiwiteit van artemisoon of DHA verbeter of geïnhibeer nie. Artemisoon (verwysing- en Pheroid® formulering) en metaboliet M1 het 'n vinnige staking in die groei van *P. falciparum* W2 parasiete veroorsaak en het ook gelei tot die vorming van dormant ring stadia op 'n wyse soortgelyk aan dié van DHA .

Interaksie van artemisoon met p-glikoproteïen (p-gp) effluks sisteem se ATPase is ondersoek. Artemisoon stimuleer ATPase aktiwiteit op 'n konsentrasie-afhanklike wyse, terwyl die Pheroid® hierdie aktiwiteit inhibeer. Stimulasie van p-gp ATPase aktiwiteit was vier keer hoër in menslike MDR1 uitgedrukte insek selmembrane as in dié van die cynomolgus aap. Artemisoon alleen en artemisoon in die Pheroid® vesikels het matige apikale tot basolaterale en hoë basolaterale tot apikale deurlaatbaarheid ( $P_{app}$ ) deur Caco-2 selle getoon. Die  $P_{app}$  uitvloeit verhouding van artemisoon en artemisoon vasgevang in Pheroid® vesikels was albei >5, en het tot ~1 gedaal wanneer die p-gp inhibitor, verapamil,

bygevoeg is. Artemisoan is dus 'n substraat vir soogdier p-gp. Die sitotoksiese eienskappe van Pheroid® op Caco-2 selle is bepaal en die pro-Pheroid® blyk nie-toksies te wees by konsentrasies van  $\leq 1,25\%$  nie.

Blouaap plasma veroorsaak teenliggaam-bemiddelde inhibisie van die vermeerdering van *P. falciparum* parasiete. Inaktivering van plasma deur verhitting of proteïn A behandeling is gebruik vir die vernietiging van die groei- inhiberende effek van die geneesmiddel-vrye plasma. Artemisoan bevattende plasma monsters kon nie ontleed word deur die *ex-vivo* bioassay metode nie. Die dubbele merking ROS metode was nie bruikbaar vir die evaluering van ROS produksie deur artemisoan en die Pheroid® nie.

Ten slotte, toevoeging van artemisoan tot die Pheroid® verbeter die farmakokinetiese eienskappe van artemisoan, maar daar is nie 'n verbetering of inhibisie van die *in vitro* anti-malaria effektiwiteit nie. Die Pheroid® inhibeer beide die mikrosomale metabolisme van artemisoan en P-gp ATPase aktiwiteit en bleik nie-toksies te wees by klinies toepaslike konsentrasies.

**Sleutelwoorde:** aap, artemisoan, biobeskikbaarheid, effektiwiteit geneesmiddel aflewering, , malaria, metabolisme, opruiming, Pheroid®.

## TABLE OF CONTENTS

	<b>PAGE</b>
ABSTRACT	i
UITTREKSEL	iii
 <b>CHAPTER 1: PROBLEM STATEMENT AND AIM OF THE STUDY</b>	
Problem statement and aim of the study	1
References	7
 <b>CHAPTER 2: LITERATURE REVIEW</b>	
1. MALARIA	15
1.1 Introduction	15
1.2. The malaria parasite	16
1.3. Symptoms	18
1.3.1. Uncomplicated malaria	18
1.3.2. Complicated (severe) malaria	18
1.4. Diagnosis	19
1.5. Control strategies	21
1.5.1. Malaria control policies and strategies	21
1.5.2. Malaria prevention through vector control	21
1.5.3. Antimalarial chemotherapy	21
1.5.3.1. Quinolines	22
1.5.3.2. Antifolates	23
1.5.3.3. Antibiotics	24
1.5.3.4. Peroxides	25
1.5.4. Antimalarial chemotherapy resistance	30
1.5.5. Preventive chemotherapy	33
1.5.6. Case management: Treatment	35
1.5.6.1. Uncomplicated malaria	35
1.5.6.2. Severe/complicated malaria	36
 2. ARTEMISONE, A NOVEL ARTEMISININ DERIVATIVE	 37
2.1. Introduction	37
2.2. Synthesis and physico-chemical properties	39
2.3. The mechanism of action of artemisinins	41

2.4. Pharmacokinetics	45
2.5. Metabolism	46
2.6. Antimalarial Activities	48
2.7. Toxicity	53
3. DRUG DELIVERY OF ARTEMISININS	54
3.1. Pheroid® vesicles as a drug delivery system	55
3.2. Application of Pheroid technology as an anti-malarial (specifically artemisone) drug delivery system	58
4. REFERENCES	61
<b>CHAPTER 3: MANUSCRIPT 1</b>	
Guide for Authors: Expert Opinion on Drug Metabolism and Toxicology	82
Proof of submission	88
Title page	89
Abstract	90
1. Introduction	91
2. Methods	94
2.1. Materials	94
2.2. <i>In vivo</i> pharmacokinetic studies	94
2.2.1. Preparation of artemisone reference and test formulations	94
2.2.2. Drug administration and sample analysis	95
2.2.3. Statistical analysis	96
2.3. <i>In vitro</i> metabolism studies	97
2.3.1. Preparation of artemisone reference and test formulations	97
2.3.2. Metabolic stability and inhibitor phenotype assays	97
2.3.3. Determination on intrinsic clearance	98
2.3.4. Statistical analysis	99
2.4. Pro-Pheroid characterization	100
3. Results and discussion	100
3.1. Pro-Pheroid characterization	100
3.2. <i>In vivo</i> pharmacokinetics	101
3.2.1. LC-MS/MS assay	101
3.3. <i>In vitro</i> metabolic stability and inhibition	104
4. Discussion	112

5. Conclusion	114
6. Acknowledgements	115
7. Reference	115

#### **CHAPTER 4: MANUSCRIPT 2**

Guide for Authors: Antimicrobial Agents and Chemotherapy	123
Title page	145
Abstract	146
1. Introduction	146
2. Materials and methods	150
2.1. Drug preparation	150
2.2. <i>In vitro</i> cultivation of <i>P. falciparum</i>	151
2.3. <i>In vitro</i> antimalarial activity assay	151
2.4. <i>In vitro</i> drug dormancy	152
3. Results	153
3.1. <i>In vitro</i> antimalarial drug activity	153
3.2. <i>In vitro</i> drug induced dormancy	156
4. Discussion	157
5. Acknowledgements	160
6. References	160

#### **CHAPTER 5: MANUSCRIPT 3**

Guide for Authors: The International Journal for Parasitology	169
Title page	181
Abstract.	182
1. Introduction	183
2. Materials and methods	185
2.1. Materials	185
2.2. Preparation of solutions	186
2.2.1. ATPase assay	186
2.3. Pheroid characterization	187
2.4. Cultivation of Caco-2 cells	188
2.5. P-gp ATPase Assay	188
2.6. Cytotoxicity of the Pheroid drug delivery system (Live/Dead assay)	189
2.7. Caco-2 transport studies	190
2.8. Statistical Analysis	192
3. Results	192

3.1. Pheroid characterization	192
3.2. Effects of artemisone and Pheroid on p-gp-ATPase and p-gp drug interaction	193
3.3. Cytotoxic effects of the Pheroid particles on Caco-2 cells	197
3.4. Transport study	198
3.5. Mathematical model of the caco-2 study	202
3.5.1. The mathematical model	202
3.5.2. Parameters of the model	203
3.5.3. Results	204
4. Discussion	205
5. Conclusion	208
6. References	208

## **CHAPTER 6: MISCELLANEOUS RESULTS**

1. Introduction	213
2. Materials and Methods	214
2.1. Materials	214
2.2. Methods	215
2.2.1. Preparation of drug solutions and plasma samples	215
2.2.2. <i>In vitro</i> cultivation of <i>P. falciparum</i>	217
2.2.3. <i>In vitro</i> and <i>ex vivo</i> antimalarial activities of artemisone against <i>P. falciparum</i>	217
2.2.4. Determination of oxidative stress formation by artemisone reference and pro-Pheroid® formulation	218
2.2.5. Statistical analysis	219
3. Results	219
3.1. Pro-Pheroid® characterization	219
3.2. <i>In vitro</i> and <i>ex vivo</i> antimalarial activities of artemisone against <i>P. falciparum</i>	220
3.3. Determination of ROS formation in <i>P.falciparum</i> parasites.	224
4. Discussion	229
5. Conclusion	232
6. References	232

## **CHAPTER 7: SUMMARY AND FUTURE PROSPECTS**

1. Introduction	239
2. Summary and future prospects	239
3. References	245

## **ANNEXURES**

Annexure A	250
Annexure B	252
Annexure C	254
Annexure D	255
Annexure E	256

## LIST OF FIGURES (SHORT LIST)

### CHAPTER 2:

Figure 1.1: Countries and areas at risk of malaria transmission in 2009.	16
Figure 1.2: Illustration of the life cycle of the malaria parasite.	17
Figure 1.3: Illustrations of the different stages of <i>Plasmodium</i> .	20
Figure 1.4: Structure of several quinoline antimalarial drugs.	22
Figure 1.5: Structures of several resistance reversal agents and modified chloroquine molecules.	23
Figure 1.6: Structures of several antifolate antimalarial drugs.	24
Figure 1.7: Structures of some antibiotic antimalarial drugs.	25
Figure 1.8: Structures of artemisinin, its derivatives and Yingzhaosu A.	26
Figure 1.9: Peroxides.	26
Figure 1.10: Structures of several cyclic endoperoxides.	27
Figure 1.12: Structures of the 1,2,4-trioxolanes OZ277 and OZ439.	28
Figure 1.13: Structures of several of the 1,2,4,5-tetraoxanes.	29
Figure 1.14: Structures of examples of trioxaquinines, trioxolaquinines and tetraoxaquinines.	30
Figure 1.15: Sites where suspected or confirmed artemisinin resistance has been detected in therapeutic efficacy studies conducted from 2007 to 2012	32
Figure 2.1: The global portfolio of anti malarial medicines under development	39
Figure 2.2: The synthesis of artemisone from dihydroartemisinin	40
Figure 2.3: Artemisone and metabolites M1–M5	47
Figure 3.1: Size distribution of a typical Pheroid formulation measured by CLSM	57
Figure 3.2: Confocal micrographs	58

### CHAPTER 3:

Figure 1: Artemisone and the metabolites M1-5 formed during metabolism.	92
Figure 2: Effect of the Pheroid delivery system on artemisone and metabolite M1 plasma concentration.	103
Figure 3: Metabolic stability of artemisone reference standard and pro-Pheroid formulation in a) HLM, b) MLM, c) HIM and (d) MIM.	105

Figure 4: Selected ion chromatograms of artemisone and its metabolites.	108
Figure 5: Percentage representation of the artemisone parent compound depletion and metabolite formation.	109
Figure 6: Effect of the Pheroid delivery system on artemisone clearance in the presence of the CYP3A4 inhibitor azamulin.	110
Figure 7: a) The effect of Pheroid technology on artemisone metabolism in HLM vs. rCYP3A4, b) Percentage representation of the artemisone parent compound depletion and metabolite formation in HLM and rCYP3A4.	111

#### **CHAPTER 4:**

Figure 1: Structure diagrams of artemisone and its metabolite M1.	148
Figure 2: <i>In vitro</i> antimalarial activities against six <i>P. falciparum</i> strains.	155
Figure 3: Comparison of control parasites with parasites exposed to drugs.	156
Figure 4: The effect of DHA, AMS), artemisone entrapped into the Pheroid, metabolite M1 and MQ against the <i>P. falciparum</i> W2 strain.	157

#### **CHAPTER 5:**

Figure 1: CLSM micrograph of the Pheroid vesicle formulations.	193
Figure 2: The effect of artemisone on the p-gp ATPase activity.	194
Figure 3: The effect of verapamil, artemisone and artemisone-pro-Pheroid on the p-gp ATPase activity in human MDR1 and cynomolgus monkey Mdr1 expressed insect cell membranes.	195
Figure 5: The toxicity of the Pheroid on Caco-2 cells was analysed by Caco-2 cell attachment	198
Figure 6: Artemisone (diamonds) and artemisone-Pheroid (squares) transport kinetics.	199
Figure 7: a) The apparent permeabilities of artemisone and artemisone-Pheroid	201

#### **CHAPTER 6:**

Figure 1: Confocal laser scanning electron microscopy micrograph	220
Figure 2: Effect of the Pheroid® formulation on the antimalarial activity of artemisone.	221
Figure 3: The effect of plasma dilutions from plasma collected from three time intervals on parasite proliferation.	221
Figure 4: The effect of drug free plasma concentration on the parasite proliferation.	222
Figure 5: The effect of heat inactivated artemisone spiked plasma concentration on parasite proliferation.	223
Figure 6: The effect of (a) heat inactivated and (b) protein A inactivated artemisone spiked plasma concentration on the parasite proliferation.	223

Figure 7: Two-dimensional plots in uninfected, ring and trophozoite stage infected red blood cells analyzed by flow cytometry.	225
Figure 8: DCF fluorescent signals obtained with drug treatment of trophozoite stage parasites.	225
Figure 9: DCF fluorescent signals obtained with drug treatment of trophozoite stage parasites.	226
Figure 10: DCF fluorescent signals obtained with drug treatment of trophozoite stage parasites.	227
Figure 11: DCF fluorescent signals obtained with drug treatment of trophozoite stage parasites.	228

## LIST OF TABLES (SHORT LIST)

### CHAPTER 2:

Table 1.1: Dates of the first reports of antimalarial drug resistance.	31
Table 2.1: Aqueous solubility and octanol–water partition coefficients.	41
Table 2.2: <i>In vitro</i> and <i>ex vivo</i> activities artemisone and other artemisinin, synthetic peroxides and standard antimalarial drugs.	49
Table 2.3: <i>In vitro</i> activities of artemisone and other artemisinins.	50
Table 2.4: <i>In vivo</i> activity of artemisone and artesunate.	50
Table 2.5: <i>In vivo</i> activity of artemisone and artesunate.	51
Table 2.6: Responses of malaria-infected monkeys to oral treatment with artemisone alone or with artemisone combined with mefloquine, amodiaquine or clindamycin.	52
Table 3.1: The <i>in vitro</i> efficacy results of artemisone reference and artemisone entrapped into the Pheroid® drug delivery system.	60
Table 3.2: The <i>in vivo</i> bioavailability results of artemisone reference and artemisone entrapped into the Pheroid® drug delivery system	60

### CHAPTER 3:

Table 1: The particle size of the different Pheroid formulations	101
Table 2: The plasma pharmacokinetics of artemisone	102
Table 3: The <i>in vitro</i> intrinsic clearance of the artemisone reference and artemisone pro-Pheroid formulation	106

### CHAPTER 4:

Table 1. <i>In vitro</i> antimalarial activity against six <i>P.falciparum</i> strains.	154
---	-----

**CHAPTER 5:**

Table 1: The particle size, span and zeta potential of the different Pheroid formulations	193
Table 2: The effect of pro-Pheroid on the p-gp ATPase activity of the substrates	197
Table 3: The apparent permeabilities	201
Table 4: The parameter values that reproduced the experimental values	204

**CHAPTER 6:**

Table 1: The composition of the Pheroid <sup>®</sup> formulations used in the drug susceptibility and ROS studies.	216
Table 2: The particle size of the different Pheroid <sup>®</sup> formulations	220

**CHAPTER 7:**

Table 1: The composition of the starting oil phase of the two formulations used in the <i>in vitro</i> efficacy experiments.	240
--	-----